InSightec

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Phase 31

By Therapeutic Area

top 1

Oncology

1100%

R&D Momentum

41/100

Pipeline Velocity

6/100

Trial Completion Rate

100/100

Pipeline Concentration

100/100

Pipeline Freshness

61/100

Activity

Recent Activity

Last 14 days

Sep 9, 2026

Completed

A Clinical Study To Evaluate the Safety and Effectiveness of MR Guided Focused Ultrasound Surgery in the Treatment of Early Breast Carcinomas

Sep 9, 2026

Completed

Study of ExAblate Focused Ultrasound Ablation of Breast Cancer Under MR Guidance (MRgFUS) and MRI Evaluation of Ablation

Earlier

Sep 4, 2026TrialAssessment of Safety and Feasibility of ExAblate Neuro System to Perform Auto-Focusing Echo Imaging in Patients With Idiopathic Essential Tremor With Medication Refractory Tremor

Sep 1, 2026TrialInternational, Multicenter, Investigator Blinded, Randomized And Controlled Essential Tremor Trial With Staged-Bilateral FUS

Aug 25, 2026TrialAn MR Guided Focused Ultrasound (MRgFUS) Randomized Trial Using the Exablate Neuro System to Assess the Effectiveness and Safety Outcomes of Unilateral and Staged Bilateral Ablation in the Subthalamic Region Involving the Pallidothalamic Tract (PTT) in Advanced Parkinson's Disease (PD) With Motor Complications.

Aug 20, 2026TrialA Randomized Pivotal Study Assessing the Safety and Efficacy of Targeted Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound During the Standard of Care Treatment of Brain Metastases of Non-small Cell Lung Cancer (NSCLC) Origin

Aug 14, 2026TrialA Randomized Feasibility Clinical Trial of the Management of the Medically-Refractory Motor Symptoms of Advanced Idiopathic Parkinson's Disease With Unilateral Lesioning of the Subthalamic Nucleus Using the ExAblate Transcranial System

Jun 30, 2026TrialA Feasibility Safety Study Using the ExAblate 4000 System in the Management of Benign Centrally-Located Intracranial Tumors Which Require Clinical Intervention in Pediatric and Young Adult Subjects

4 more events

Jun 27, 2026TrialA Feasibility Clinical Trial of Exablate for Low Intensity Focused Ultrasound Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Abuse Disorders (SUDs)

Jun 25, 2026TrialA Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Thalamotomy in the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease

Aug 1, 2024TrialA Prospective, Randomized, Controlled Trial to Test Safety and Effectiveness of Unilateral Exablate MR-guided Focused Ultrasound Subthalamotomy in Patients With Early-Stage Parkinson's Disease

Jan 4, 2023TrialBlood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Oncology

Brain Tumor

Iptilimumab

Oncology

Brain Tumor

IptilimumabPhase 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)